Baird Upgrades Biogen to Outperform, Raises Price Target to $340

Baird analyst Brian Skorney upgrades Biogen (NASDAQ:BIIB) from Neutral to Outperform and raises the price target from $224 to $340.

byBenzinga Newsdesk

September 28, 2022

1 minute read

Baird analyst Brian Skorney upgrades Biogen (NASDAQ:BIIB) from Neutral to Outperform and raises the price target from $224 to $340.

Eastern Bankshares Q3 EPS $0.22 Beats $0.21 Estimate, Sales $145.90M Beat $106.57M Estimate

By Bill Haddad

Today, 12:41 PM

Eastern Bankshares (NASDAQ:EBC) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $0.21 by 4.76 percent. The company reported quarterly sales of $145.90 million which beat the

EBC

42 Stocks Moving In Thursday’s Mid-Day Session

By Lisa Levin

Today, 12:41 PM

Gainers Orphazyme A/S (NASDAQ: ORPH) surged 105% to $10.71.

AEI

Axsome Shares Shoot Higher As FDA Approves Major Depressive Disorder Candidate

By Ragothaman Srinivasan

Today, 12:41 PM

The U.S. Food and Drug Administration (FDA) has approved Axsome Therapeutics’ (NASDAQ: AXSM) lead asset AUVELITY (dextromethorphan HBr -bupropion HCl) extended-release tablets for the treatment of major depressive disorder (MDD) in adults.

AXSM

One More Activision Blizzard Employee Brings Allegations Of Workplace Sexual Harassment

By Anusuya Lahiri

Today, 12:41 PM

An anonymous Jane Doe prosecuted Activision Blizzard, Inc (NASDAQ: ATVI) for sexual harassment, gender discrimination, and sexual battery, among other complaints.

ATVI

Baird Upgrades Biogen to Outperform, Raises Price Target to $340

Related Posts

Eastern Bankshares Q3 EPS $0.22 Beats $0.21 Estimate, Sales $145.90M Beat $106.57M Estimate

42 Stocks Moving In Thursday’s Mid-Day Session

Axsome Shares Shoot Higher As FDA Approves Major Depressive Disorder Candidate

One More Activision Blizzard Employee Brings Allegations Of Workplace Sexual Harassment